NCT01912391View on ClinicalTrials.gov

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Borderline Personality Disorder
Interventions
DRUG

Selegiline

The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.

DRUG

Placebo (for Selegiline)

Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch

Trial Locations (1)

93720

Mood and Anxiety Research, Inc, Fresno

All Listed Sponsors
lead

Mood and Anxiety Research, Inc

OTHER

NCT01912391 - Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder | Biotech Hunter | Biotech Hunter